Hyejung Lee

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Antiplatelet Therapy

Acute Coronary Syndrome

Top Venues

Translational and clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

A-Young Yang, Hyounggyoon Yoo, Wonsuk Shin, Yil-Seob Lee, Hyejung Lee, Sung-Eun Kim, Anhye Kim
Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation. Translational and clinical pharmacology 31 (1) (2023)
JungJin Oh, Eunsol Yang, In-Jin Jang, Hyejung Lee, Hokyun Yoo, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics 15 (2) (2023)
JungJin Oh, Eunsol Yang, In-Jin Jang, Hyejung Lee, Hokyun Yoo, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics 15 (2) (2023)
JungJin Oh, Eunsol Yang, In-Jin Jang, Hyejung Lee, Hokyun Yoo, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics 15 (2) (2023)